<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yagi-Utsumi M</submitter><funding>Ministry of Education, Culture, Sports, Science and Technology</funding><funding>Precursory Research for Embryonic Science and Technology</funding><funding>Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences</funding><funding>Japan Society for the Promotion of Science</funding><funding>Nagoya City University</funding><pagination>2648-2657</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10401643</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(15)</volume><pubmed_abstract>Alzheimer's disease (AD) is associated with progressive accumulation of amyloid-β (Aβ) cross-β fibrils in the brain. Aβ species tightly associated with GM1 ganglioside, a glycosphingolipid abundant in neuronal membranes, promote amyloid fibril formation; therefore, they could be attractive clinical targets. However, the active conformational state of Aβ in GM1-containing lipid membranes is still unknown. The present solid-state nuclear magnetic resonance study revealed a nonfibrillar Aβ assemblage characterized by a double-layered antiparallel β-structure specifically formed on GM1 ganglioside clusters. Our data show that this unique assemblage was not transformed into fibrils on GM1-containing membranes but could promote conversion of monomeric Aβ into fibrils, suggesting that a solvent-exposed hydrophobic layer provides a catalytic surface evoking Aβ fibril formation. Our findings offer structural clues for designing drugs targeting catalytically active Aβ conformational species for the development of anti-AD therapeutics.</pubmed_abstract><journal>ACS chemical neuroscience</journal><pubmed_title>The Double-Layered Structure of Amyloid-β Assemblage on GM1-Containing Membranes Catalytically Promotes Fibrillization.</pubmed_title><pmcid>PMC10401643</pmcid><funding_grant_id>22EXC338</funding_grant_id><funding_grant_id>JP19K05552</funding_grant_id><funding_grant_id>JP21K06040</funding_grant_id><funding_grant_id>2212008</funding_grant_id><funding_grant_id>JPMJPR22AC</funding_grant_id><funding_grant_id>23EXC305</funding_grant_id><funding_grant_id>JPMXP09S19MS1049</funding_grant_id><funding_grant_id>JP21K06118</funding_grant_id><funding_grant_id>2222004</funding_grant_id><funding_grant_id>JP16K05858</funding_grant_id><funding_grant_id>JPMXP09S18MS1087</funding_grant_id><funding_grant_id>JPMXP09S18MS1055</funding_grant_id><funding_grant_id>JPMXP09S17MS1095</funding_grant_id><funding_grant_id>JP19K07041</funding_grant_id><pubmed_authors>Nishimura K</pubmed_authors><pubmed_authors>Yagi-Utsumi M</pubmed_authors><pubmed_authors>Okumura H</pubmed_authors><pubmed_authors>Kato K</pubmed_authors><pubmed_authors>Itoh SG</pubmed_authors><pubmed_authors>Yanagisawa K</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Double-Layered Structure of Amyloid-β Assemblage on GM1-Containing Membranes Catalytically Promotes Fibrillization.</name><description>Alzheimer's disease (AD) is associated with progressive accumulation of amyloid-β (Aβ) cross-β fibrils in the brain. Aβ species tightly associated with GM1 ganglioside, a glycosphingolipid abundant in neuronal membranes, promote amyloid fibril formation; therefore, they could be attractive clinical targets. However, the active conformational state of Aβ in GM1-containing lipid membranes is still unknown. The present solid-state nuclear magnetic resonance study revealed a nonfibrillar Aβ assemblage characterized by a double-layered antiparallel β-structure specifically formed on GM1 ganglioside clusters. Our data show that this unique assemblage was not transformed into fibrils on GM1-containing membranes but could promote conversion of monomeric Aβ into fibrils, suggesting that a solvent-exposed hydrophobic layer provides a catalytic surface evoking Aβ fibril formation. Our findings offer structural clues for designing drugs targeting catalytically active Aβ conformational species for the development of anti-AD therapeutics.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Aug</publication><modification>2025-04-26T11:30:05.318Z</modification><creation>2025-04-06T13:42:39.617Z</creation></dates><accession>S-EPMC10401643</accession><cross_references><pubmed>37482658</pubmed><doi>10.1021/acschemneuro.3c00192</doi></cross_references></HashMap>